Last reviewed · How we verify
NCT05278182: NXT-ASSESS
A Placebo Controlled, Double-blind, Randomised Trial for Assessment of the Efficacy of Naoxintong Capsules in the Treatment of Coronary Atherosclerotic Plaque in Patients With Acute Myocardial Infarct on the Basis of Optimal Medical Therapy (Aspirin,Statins, Clopidogrel, Etc.)
NA trial testing Naoxintong Capsule in Atherosclerotic Cardiovascular Disease in 80 participants. Status unknown.
30 June 2025
Quick facts
| Lead sponsor | Chinese Academy of Medical Sciences, Fuwai Hospital |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 80 |
| Start date | 1 December 2022 |
| Primary completion | 30 June 2025 |
| Estimated completion | 30 June 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Naoxintong Capsule — full drug profile →
- Placebo
Conditions studied
- Atherosclerotic Cardiovascular Disease — all drugs for Atherosclerotic Cardiovascular Disease →
Sponsor
Chinese Academy of Medical Sciences, Fuwai Hospital
Who can join
Adults 18 to 75, any sex, with Atherosclerotic Cardiovascular Disease. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Plaque composition
Time frame: 12 months
The change of plaque composition by virtual histology intravascular ultrasound imaging in subjects who take Naoxintong capsules and placebo in post-percutaneous coronary intervention follow-up -
Plaque fibrous cap thickness
Time frame: 12 months
The change of plaque fibrous cap thickness measured by optical coherence tomography in subjects who take Naoxintong capsules and placebo during post-percutaneous coronary intervention follow-up
Sponsor's own description
To evaluate and compare the change of plaque composition by VH-IVUS imaging in subjects who take NXT and placebo in post-PCI of AMI patients during 12 months follow-up.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05278182
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Atherosclerotic Cardiovascular Disease
Currently open trials in the same condition.
- NCT07034690 — Study to Evaluate the Impact of a Targeted Lipid Optimization Program on LDL-C Control in At-risk Adult Patients With Dy · Phase 4 · recruiting
- NCT06424860 — Fish Oil, Metformin and Heart Health in PCOS · Phase 1 · recruiting
- NCT06962488 — Polygenic Risk Score Implementation and Stratification for Managing Blood Pressure · NA · recruiting
- NCT07037433 — Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiov · Phase 3 · recruiting
- NCT06875973 — Pelacarsen Roll-over Extension Program · Phase 3 · recruiting
Other Chinese Academy of Medical Sciences, Fuwai Hospital trials
Trials by the same sponsor.
- NCT07450196 — A Prospective, Multicenter, Observational Study Evaluating Safety and Effectiveness of SAPIEN 3 Transcatheter Aortic Val · not yet recruiting
- NCT07511309 — FFR-Guided Revascularization in Atherosclerotic Renal Artery Stenosis: A Randomized Controlled Trial · NA · not yet recruiting
- NCT07054541 — A Novel Echocardiography-Guided Strategy for Percutateous Closure of Atrial Septal Defect Assisted by PannaWire · Phase 4 · not yet recruiting
- NCT07458672 — TAVR for Aortic Regurgitation Under TTE Guidance · NA · not yet recruiting
- NCT07462325 — Proteomic and Inflammatory Omics Changes With Colchicine Therapy in Coronary Heart Disease · Phase 4 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05278182 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chinese Academy of Medical Sciences, Fuwai Hospital
- Last refreshed: 18 May 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05278182.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing